California-based AliveCor, an AI-enabled remote electrocardiogram (ECG) device manufacturer, will be collaborating with global biopharma manufacturer AstraZeneca to study disease management solutions for cardiovascular, kidney, and metabolism-related conditions.
The partnership will use AliveCor’s Kardia-K AI technology as a non-invasive means of measuring a patient’s potassium levels, which at elevated levels can be a sign of kidney-related issues.
Founded in 2010, AliveCor develops remote patient monitoring devices under its flagship brand, KardiaMobile. The devices track a user’s heartbeat and display the results on a mobile. In November 2020, AliveCor concluded a Series E funding round that brought the company’s total funding up to USD 154.3 million.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.